A Study of the Safety, Tolerability & Efficacy of Long-term Administration

Status Terminated

Clinical Trial Summary

This is a phase III, multicenter, open-label, uncontrolled extension study in male subjects with DMD open to eligible US and Canadian subjects who previously participated in the following studies of drisapersen: DMD114876, DMD114044 and DMD114349. Subjects will receive 6mg/kg subcutaneous drisapersen on a weekly basis. For subjects who have previously experienced significant safety or tolerability issues or who experience these during the study, there is the potential of an alternate intermittent dosing arm that will be given as a regimen of 6 mg/kg weekly for 8 weeks followed by 4 weeks off treatment. For subjects who experience or have previously experienced significant safety/tolerability issues, side effects or reactions or intermittent dosing, intravenous dosing will be made available.

Clinical Trial Description

In Part A of the study (DMD115501, original protocol), 21 subjects entered the study at 3 US sites and completed up to 14 weeks of treatment, and up to 22 weeks of follow-up. This protocol amendment, Part B of the study will include up to 13 more US and Canadian centers, and up to 51 more subjects. In total the study will enroll approximately 72 subjects. All subjects will commence Part B at screening and follow the study schedule.

The primary dosing arm is drisapersen 6 mg/kg as SC injection(s) once a week. For subjects who have previously experienced significant safety or tolerability issues or who experience these during the study, there is the potential of an alternate intermittent dosing arm that will be given as a regimen of 6 mg/kg/wk for 8 weeks followed by 4 weeks of treatment. For subjects who experience or have previously experienced significant safety/tolerability issues, intravenous dosing will be made available.

This study does not have a minimum duration of participation. Subjects will have varying times of study participation depending on when they enter from one of the eligible studies, and will be permitted to continue in this study until such a time that they withdraw based on protocol-defined criteria, or BioMarin stops the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01803412
Study type	Interventional
Source	BioMarin Pharmaceutical
Contact
Status	Terminated
Phase	Phase 3
Start date	May 1, 2013
Completion date	October 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01480245` - Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy	Phase 3
Completed	`NCT01153932` - Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT00027391` - Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)	N/A
Recruiting	`NCT04392518` - Telerehabilitation in Proximal Muscle Weakness	N/A
Completed	`NCT03851107` - The Effectiveness of Participation-focused Interventions on Body Functions of Youth With Physical Disabilities	N/A
Completed	`NCT01462292` - A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)	Phase 2
Recruiting	`NCT06094205` - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)	N/A
Recruiting	`NCT05724173` - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia	N/A
Recruiting	`NCT03698149` - ECoG BMI for Motor and Speech Control	N/A
Active, not recruiting	`NCT03811301` - [BrainConnexion] - Neurodevice Phase I Trial	N/A
Completed	`NCT05881122` - Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability	N/A
Completed	`NCT04154098` - Evaluation of a Textile Scapula Orthosis	N/A
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Enrolling by invitation	`NCT04009408` - Expiratory Muscle Strength Training (EMST) in Neuromuscular Disorders	N/A
Active, not recruiting	`NCT00674843` - The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies	Phase 1
Recruiting	`NCT02109692` - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies	N/A
Active, not recruiting	`NCT04045158` - Diaphragm Ultrasound in Neuromuscular Disorders
Not yet recruiting	`NCT03508583` - Turkish Version of The Measure of Processes of Care (MPOC)
Completed	`NCT03406780` - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT01826487` - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms